Kresmed Sp. z o. o.
- Address
- lock Available on a paid plan
Kresmed Sp. z o. o. - Cardiovascular and Renal Research Center
Kresmed Sp. z o. o. is a clinical research facility specializing in advanced cardiovascular therapeutics with particular emphasis on complex patients with multiple comorbidities. The center demonstrates expertise in conducting Phase III pharmaceutical trials for novel treatment approaches in patients with concurrent cardiac and renal impairments.
- Heart failure management and cardiovascular mortality reduction
- Chronic kidney disease comorbid with cardiovascular conditions
- Combination therapy evaluation for cardiorenal syndrome
The facility focuses on evaluating innovative pharmacological combinations including balcinrenone and dapagliflozin for patients with chronic heart failure and impaired kidney function. Their research portfolio addresses critical therapeutic gaps in managing patients with recent heart failure events, assessing both hospitalization prevention and cardiovascular mortality outcomes in this high-risk population.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 4 therapeutic areas and 15 of 18 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 3 by active trials.
- 1AstraZeneca AB5active
lock +2 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1AstraZeneca AB7trials
lock +1 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 1 624 other sites in Poland
Therapeutic Area Benchmark — Poland
Select a therapeutic area to compare against other sites in Poland.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Poland
Market Share
Country: Poland
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Kresmed Sp. z o. o.
lock Showing 1 of 16 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 3 Randomized, Placebo-Controlled Clinical Study to Evaluate the Efficacy and Safety of MK-0616 in Reducing Major Adverse Cardiovascular Events in Participants at High Cardiovascular Risk | Merck Sharp & Dohme LLC | Phase III | Not Recruiting | Jun 2024 | — |
IMP list
lock Showing 1 of 18 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Dapagliflozin | 5 | Unknown | 2024-07-12 | 2025-05-06 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.